白血病患者血浆中分子物质含量测定的临床意义(英文)

THE CLINICAL SIGNIFICANCE OF DETERMINATION OF PLASMA MIDDLE MOLECULAR SUBSTANCES IN PATIENTS WITH LEUKEMIA

本文测定了100例白血病患者血浆中分子物质的含量,发现白血病患者血浆中分子物质含量在发病期及化疗中均明显高于正常人,化疗后复发者或出现各种严重并发症者仍明显高于正常人,但化疗后部分或完全缓解者其含量基本降至正常。所以我们认为,测定白血病患者血浆中分子物质含量可作为观察疗效和判定预后的一项辅助指标。

The plasma middle molecular substances(MMS)level was measured in some patients with leukimia. The mean value of MMS were increased significantly in patients with leukemia in prechemotherapy period and during chemotherapy. It was also increased in relapse, patients or in the ones with severe complications. But it was decreased to normal level when patients got partial or complete remission. So it was suggested that the determination of plasma MMS in cases of leukemia provided a reliable means for monitoring the response to treatment and evaluating prognosis.